AI Contributes to Early Detection of Clinically Relevant Breast Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 13, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, Feb. 13, 2025 -- Artificial intelligence (AI) contributes to early detection of clinically relevant breast cancer, according to a study published online Feb. 3 in The Lancet Digital Health.

Veronica Hernström, M.D., from Lund University in Sweden, and colleagues conducted a randomized, controlled, parallel-group, noninferiority trial within the Swedish national screening program involving women recruited at four screening sites who were eligible for mammography screening. Participants were randomly assigned to AI-supported screening, which was used to triage screening examinations to single or double reading, or to standard double reading.

The researchers found that AI-supported screening among 53,043 participants resulted in 338 cancers detected and 1,110 recalls, while standard screening among 52,872 participants resulted in 262 cancers detected and 1,027 recalls. Cancer detection rates were 6.4 and 5.0 per 1,000 screened participants in the intervention and control groups (ratio, 1.29), respectively. AI-supported screening yielded increased detection of invasive cancers (270 versus 217; proportion ratio, 1.24), which were mostly small lymph node-negative cancers. There was also an increased detection of in situ cancers with AI-supported screening (68 versus 45; proportion ratio of 1.51); about half of the increased detection was high-grade in situ cancer. Compared with the control group, the intervention group had significantly higher positive predictive value of recall, with a ratio of 1.19. There were 61,248 and 109,692 screen readings in the intervention and control groups, respectively, resulting in a 44.2 percent reduction in the screen-reading workload.

"The use of AI did not negatively influence the rates of recalls, false positives, or consensus meetings and the screen-reading workload was reduced by almost half," the authors write.

One author disclosed ties to the pharmaceutical and medical technology industries.

Abstract/Full Text

Stay up to date on the latest in health — Click here to subscribe to our weekly newsletter!

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-14 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords